CRL logo

CRL EBITDA

Annual EBITDA

$581.14 M
-$450.98 M-43.69%

December 28, 2024

Summary

Performance

1-Year Change

-43.69%

3-Year Change

-29.14%

5-Year Change

+3.21%

15-Year Change

+26.92%

CRL EBITDA Chart

Add series to chart
Add series to chart(max: 6)
company, ETF, index, featured screener or watchlist
series name
Suggested series

Highlights

Sector Rank

92.73%
CRL annual EBITDA is higher than 92.73% of companies in Healthcare sector

High & Low

All-time High

$1.03 B
CRL annual EBITDA is currently -43.69% below its historical high of $1.03 billion

3-Year Low

$581.14 M
CRL annual EBITDA is currently at its 3-year low

Earnings dates

Last Annual Earnings Report Date

Dec 28, 2024
CRL previous annual earnings announcement was published on Dec 28, 2024

Next Annual Earnings Report Date

N/A
CRL next annual earnings announcement has not yet been scheduled

OtherCRLprofitabilitymetrics:

Annual Revenue

$4.05 B
CRL annual revenue is $4.05 billion

Annual Net Income

$22.20 M
CRL annual net profit is $22.20 million

Annual EBIT

$219.40 M
CRL annual earnings before interest & taxes is $219.40 million

Annual EPS

$0.20
CRL annual earnings per share is $0.20

Quarterly EBITDA

N/A

December 28, 2024

Summary

Performance

3-Month Change

-

1-Year Change

-

3-Year Change

-

5-Year Change

-

CRL Quarterly EBITDA Chart

Add series to chart
Add series to chart(max: 6)
company, ETF, index, featured screener or watchlist
series name
Suggested series

High & Low

All-time High

$357.25 M
CRL quarterly EBITDA is currently at an all-time high

3-Year Low

$195.58 M
CRL quarterly EBITDA is currently at its 3-year low

Earnings dates

Last Quarterly Earnings Report Date

Dec 28, 2024
CRL previous earnings announcement was published on Dec 28, 2024

Next Quarterly Earnings Report Date

May 9, 2025
CRL next earnings announcement is scheduled for May 9, 2025

OtherCRLprofitabilitymetrics:

Quarterly Revenue

$1.00 B
CRL quarterly revenue is $1.00 billion

Quarterly Net Income

-$213.41 M
CRL quarterly net profit is -$213.41 million

Quarterly EBIT

-
CRL quarterly earnings before interest & taxes value is unknown

Quarterly EPS

-$4.22
CRL quarterly earnings per share is -$4.22

TTM EBITDA

N/A

December 28, 2024

Summary

Performance

3-Month Change

-

1-Year Change

-

3-Year Change

-

5-Year Change

-

CRL TTM EBITDA Chart

Add series to chart
Add series to chart(max: 6)
company, ETF, index, featured screener or watchlist
series name
Suggested series

High & Low

All-time High

$1.07 B
CRL TTM EBITDA is currently at an all-time high

3-Year Low

$820.16 M
CRL TTM EBITDA is currently at its 3-year low

Earnings dates

Last Quarterly Earnings Report Date

Dec 28, 2024
CRL previous earnings announcement was published on Dec 28, 2024

Next Quarterly Earnings Report Date

May 9, 2025
CRL next earnings announcement is scheduled for May 9, 2025

OtherCRLprofitabilitymetrics:

TTM Revenue

$4.05 B
CRL TTM revenue is $4.05 billion

TTM Net Income

$22.20 M
CRL TTM net profit is $22.20 million

TTM EBIT

-
CRL TTM earnings before interest & taxes value is unknown

TTM EPS

$0.15
CRL TTM earnings per share is $0.15

EBITDA Formula

EBITDA = Net Income + Interest + Taxes + Depreciation + Amortization

Annual EBITDA

$581.14 M
CRL annual EBITDA is $581.14 million

Annual Net Income

$22.20 M
CRL annual net profit is $22.20 million

Annual Interest Expense

$126.29 M
CRL annual interest expense is $126.29 million

Annual Income Tax

$67.82 M
CRL annual income tax is $67.82 million

Annual D&A

$361.74 M
CRL annual depreciation & amortization is $361.74 million

CRL EBITDA Trends

PeriodPeriodAnnualAnnualQuarterlyQuarterlyTTMTTM
1 y1 year-43.7%--
3 y3 years-29.1%--
5 y5 years+3.2%--

CRL EBITDA Highs & Lows

PeriodPeriodAnnual vs highAnnual vs highAnnual vs lowAnnual vs lowQuarter. vs highQuarter. vs highQuarter. vs lowQuarter. vs lowTTM vs highTTM vs highTTM vs lowTTM vs low
3 y3-year-43.7%at low
5 y5-year-43.7%+3.2%
alltimeall time-43.7%+263.3%

Charles River Laboratories International EBITDA History

DateAnnualQuarterlyTTM
Dec 2024
$581.14 M(-43.7%)
-
-
Sep 2024
-
$209.72 M(-12.1%)
$990.36 M(-1.6%)
Jun 2024
-
$238.50 M(+8.7%)
$1.01 B(-0.3%)
Mar 2024
-
$219.37 M(-32.0%)
$1.01 B(-2.2%)
Dec 2023
$1.03 B(+4.7%)
$322.76 M(+43.1%)
$1.03 B(-3.2%)
Sep 2023
-
$225.49 M(-6.6%)
$1.07 B(+1.6%)
Jun 2023
-
$241.38 M(-0.5%)
$1.05 B(+1.7%)
Mar 2023
-
$242.49 M(-32.1%)
$1.03 B(+4.8%)
Dec 2022
$986.15 M(+20.2%)
$357.25 M(+70.9%)
$986.15 M(+13.2%)
Sep 2022
-
$209.09 M(-6.8%)
$871.33 M(+0.1%)
Jun 2022
-
$224.24 M(+14.7%)
$870.66 M(+1.5%)
Mar 2022
-
$195.58 M(-19.3%)
$858.21 M(+4.6%)
Dec 2021
$820.16 M(+6.7%)
$242.43 M(+16.3%)
$820.16 M(-2.8%)
Sep 2021
-
$208.41 M(-1.6%)
$844.18 M(-0.6%)
Jun 2021
-
$211.79 M(+34.4%)
$849.49 M(+6.4%)
Mar 2021
-
$157.53 M(-40.9%)
$798.21 M(+3.9%)
Dec 2020
$768.47 M(+36.5%)
$266.45 M(+24.7%)
$768.47 M(+12.4%)
Sep 2020
-
$213.72 M(+33.2%)
$683.78 M(+13.8%)
Jun 2020
-
$160.51 M(+25.6%)
$600.75 M(+5.5%)
Mar 2020
-
$127.79 M(-29.7%)
$569.21 M(+1.1%)
Dec 2019
$563.06 M(+11.0%)
$181.76 M(+39.1%)
$563.06 M(+9.4%)
Sep 2019
-
$130.69 M(+1.3%)
$514.67 M(-0.7%)
Jun 2019
-
$128.97 M(+6.0%)
$518.07 M(-0.6%)
Mar 2019
-
$121.64 M(-8.8%)
$521.43 M(+2.8%)
Dec 2018
$507.23 M(+10.8%)
$133.37 M(-0.5%)
$507.23 M(+4.8%)
Sep 2018
-
$134.09 M(+1.3%)
$484.12 M(+4.3%)
Jun 2018
-
$132.33 M(+23.2%)
$464.10 M(+3.6%)
Mar 2018
-
$107.44 M(-2.6%)
$447.89 M(-2.2%)
Dec 2017
$457.89 M(+21.4%)
$110.26 M(-3.3%)
$457.89 M(+0.8%)
Sep 2017
-
$114.07 M(-1.8%)
$454.41 M(+4.5%)
Jun 2017
-
$116.12 M(-1.1%)
$434.78 M(+4.9%)
Mar 2017
-
$117.44 M(+10.0%)
$414.31 M(+9.8%)
Dec 2016
$377.29 M(+23.5%)
$106.78 M(+13.1%)
$377.29 M(+7.8%)
Sep 2016
-
$94.44 M(-1.3%)
$349.88 M(+4.1%)
Jun 2016
-
$95.65 M(+18.9%)
$336.25 M(+2.4%)
Mar 2016
-
$80.42 M(+1.3%)
$328.45 M(+7.6%)
Dec 2015
$305.38 M(+6.8%)
$79.36 M(-1.8%)
$305.38 M(+3.5%)
Sep 2015
-
$80.82 M(-8.0%)
$294.99 M(+2.7%)
Jun 2015
-
$87.85 M(+53.2%)
$287.13 M(+3.5%)
Mar 2015
-
$57.34 M(-16.9%)
$277.50 M(-3.0%)
Dec 2014
$285.99 M(+11.7%)
$68.97 M(-5.5%)
$285.99 M(+5.0%)
Sep 2014
-
$72.96 M(-6.7%)
$272.25 M(+0.4%)
Jun 2014
-
$78.22 M(+18.8%)
$271.25 M(+5.2%)
Mar 2014
-
$65.84 M(+19.2%)
$257.83 M(+0.7%)
Dec 2013
$255.93 M(+4.7%)
$55.23 M(-23.2%)
$255.93 M(+0.0%)
Sep 2013
-
$71.96 M(+11.0%)
$255.87 M(+6.0%)
Jun 2013
-
$64.80 M(+1.3%)
$241.38 M(-1.4%)
Mar 2013
-
$63.94 M(+15.9%)
$244.72 M(+0.1%)
Dec 2012
$244.36 M
$55.17 M(-4.0%)
$244.36 M(-3.3%)
Sep 2012
-
$57.46 M(-15.7%)
$252.79 M(-0.1%)
Jun 2012
-
$68.14 M(+7.2%)
$252.98 M(-2.7%)
DateAnnualQuarterlyTTM
Mar 2012
-
$63.58 M(-0.0%)
$260.12 M(-0.1%)
Dec 2011
$260.48 M(-227.0%)
$63.60 M(+10.3%)
$260.48 M(-282.3%)
Sep 2011
-
$57.65 M(-23.4%)
-$142.92 M(-16.9%)
Jun 2011
-
$75.28 M(+17.7%)
-$172.03 M(-11.7%)
Mar 2011
-
$63.94 M(-118.8%)
-$194.87 M(-5.0%)
Dec 2010
-$205.15 M(-177.9%)
-$339.80 M(-1290.3%)
-$205.15 M(-208.4%)
Sep 2010
-
$28.55 M(-45.6%)
$189.23 M(-18.3%)
Jun 2010
-
$52.43 M(-2.3%)
$231.53 M(-9.1%)
Mar 2010
-
$53.66 M(-1.7%)
$254.63 M(-3.3%)
Dec 2009
$263.20 M(-174.0%)
$54.59 M(-23.0%)
$263.20 M(-162.5%)
Sep 2009
-
$70.85 M(-6.2%)
-$421.17 M(+5.3%)
Jun 2009
-
$75.54 M(+21.4%)
-$399.97 M(+4.9%)
Mar 2009
-
$62.23 M(-109.9%)
-$381.37 M(+7.2%)
Dec 2008
-$355.82 M(-210.6%)
-$629.78 M(-784.2%)
-$355.82 M(-200.0%)
Sep 2008
-
$92.05 M(-2.2%)
$355.65 M(+1.7%)
Jun 2008
-
$94.13 M(+7.2%)
$349.82 M(+4.6%)
Mar 2008
-
$87.78 M(+7.5%)
$334.27 M(+3.9%)
Dec 2007
$321.81 M(+17.7%)
$81.68 M(-5.3%)
$321.81 M(+4.5%)
Sep 2007
-
$86.22 M(+9.7%)
$307.81 M(+4.3%)
Jun 2007
-
$78.59 M(+4.4%)
$295.00 M(+3.4%)
Mar 2007
-
$75.31 M(+11.3%)
$285.19 M(+96.8%)
Dec 2006
$273.30 M(-0.5%)
$67.69 M(-7.8%)
$144.94 M(+11.8%)
Sep 2006
-
$73.40 M(+6.7%)
$129.63 M(-6.3%)
Jun 2006
-
$68.79 M(-205.9%)
$138.34 M(+0.5%)
Mar 2006
-
-$64.93 M(-224.0%)
$137.62 M(-49.8%)
Dec 2005
$274.81 M(+36.1%)
$52.38 M(-36.2%)
$274.02 M(+0.9%)
Sep 2005
-
$82.11 M(+20.6%)
$271.66 M(+12.5%)
Jun 2005
-
$68.06 M(-4.8%)
$241.40 M(+7.0%)
Mar 2005
-
$71.47 M(+42.9%)
$225.69 M(+11.8%)
Dec 2004
$201.92 M(+19.0%)
$50.02 M(-3.5%)
$201.92 M(+2.9%)
Sep 2004
-
$51.86 M(-0.9%)
$196.18 M(+5.3%)
Jun 2004
-
$52.34 M(+9.7%)
$186.23 M(+5.6%)
Mar 2004
-
$47.70 M(+7.7%)
$176.34 M(+3.9%)
Dec 2003
$169.67 M(+14.7%)
$44.28 M(+5.7%)
$169.67 M(+3.9%)
Sep 2003
-
$41.91 M(-1.3%)
$163.25 M(+1.6%)
Jun 2003
-
$42.46 M(+3.5%)
$160.70 M(+3.8%)
Mar 2003
-
$41.03 M(+8.4%)
$154.80 M(+4.6%)
Dec 2002
$147.99 M(+24.5%)
$37.86 M(-3.8%)
$147.99 M(+5.1%)
Sep 2002
-
$39.36 M(+7.7%)
$140.80 M(+5.9%)
Jun 2002
-
$36.56 M(+6.8%)
$132.94 M(+4.0%)
Mar 2002
-
$34.22 M(+11.6%)
$127.81 M(+7.5%)
Dec 2001
$118.86 M(+41.6%)
$30.67 M(-2.6%)
$118.86 M(+11.3%)
Sep 2001
-
$31.49 M(+0.2%)
$106.78 M(+9.2%)
Jun 2001
-
$31.44 M(+24.4%)
$97.81 M(+13.3%)
Mar 2001
-
$25.27 M(+36.0%)
$86.36 M(+2.9%)
Dec 2000
$83.93 M(+43.2%)
$18.58 M(-17.5%)
$83.93 M(+28.4%)
Sep 2000
-
$22.53 M(+12.7%)
$65.35 M(+52.6%)
Jun 2000
-
$19.98 M(-12.5%)
$42.82 M(+87.5%)
Mar 2000
-
$22.84 M
$22.84 M
Dec 1999
$58.61 M(+26.8%)
-
-
Dec 1998
$46.22 M
-
-

FAQ

  • What is Charles River Laboratories International annual EBITDA?
  • What is the all time high annual EBITDA for Charles River Laboratories International?
  • What is Charles River Laboratories International annual EBITDA year-on-year change?
  • What is the all time high quarterly EBITDA for Charles River Laboratories International?
  • What is the all time high TTM EBITDA for Charles River Laboratories International?

What is Charles River Laboratories International annual EBITDA?

The current annual EBITDA of CRL is $581.14 M

What is the all time high annual EBITDA for Charles River Laboratories International?

Charles River Laboratories International all-time high annual EBITDA is $1.03 B

What is Charles River Laboratories International annual EBITDA year-on-year change?

Over the past year, CRL annual EBITDA has changed by -$450.98 M (-43.69%)

What is the all time high quarterly EBITDA for Charles River Laboratories International?

Charles River Laboratories International all-time high quarterly EBITDA is $357.25 M

What is the all time high TTM EBITDA for Charles River Laboratories International?

Charles River Laboratories International all-time high TTM EBITDA is $1.07 B